Excessive Daytime Sleepiness Market Trends Are Creating New Opportunities For Industry Leaders
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Excessive Daytime Sleepiness Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The excessive daytime sleepiness market size has experienced strong growth in recent years. It is anticipated to expand from $5.39 billion in 2025 to $5.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. This historical growth can be attributed to several factors including the rising prevalence of sleep disorders, increased awareness regarding the effects of sleep health, the expansion of sleep clinic infrastructure, the availability of pharmacological wake-promoting agents, and the broader provision of diagnostic sleep testing services.
The market for excessive daytime sleepiness is projected to experience substantial expansion over the upcoming years, reaching a valuation of $8.52 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.6%. This projected growth is largely due to factors such as the rising demand for customized sleep treatment options, the growing incorporation of digital therapeutics in sleep management, wider acceptance of remote patient monitoring, an increased emphasis on preventative sleep health, and greater investment in sleep medicine research. Key developments anticipated during this timeframe involve the wider adoption of wearable devices for sleep monitoring, an increase in combination therapy strategies, the broadening of home-based solutions for sleep disorder management, a heightened focus on early detection and screening initiatives, and improved integration of digital sleep health platforms.
Download A Free Sample Report For Comprehensive Market Insights:
#Excessive Daytime Sleepiness Market Growth Drivers And Industry Catalysts
The increasing occurrence of obstructive sleep apnea (OSA) is anticipated to stimulate the growth of the excessive daytime sleepiness (EDS) market moving forward. Obstructive sleep apnea is a sleep condition marked by recurrent breathing interruptions during sleep, caused by upper airway obstruction, which results in disrupted sleep and lower sleep quality. The rise in obstructive sleep apnea cases is attributed to increasing obesity rates, where surplus fat in the neck and throat constricts the airway, leading to breathing pauses during sleep. Excessive daytime sleepiness is a frequent and weakening symptom of obstructive sleep apnea, often persisting in a considerable number of patients, thereby necessitating focused therapeutic and management approaches. For example, in August 2026, the National Library of Medicine, a US-based medical library, estimated that by 2050, roughly 76.6 million adults aged 30–69 in the United States are projected to be impacted by obstructive sleep apnea. Consequently, the growing prevalence of obstructive sleep apnea is propelling the expansion of the excessive daytime sleepiness market.
Excessive Daytime Sleepiness Market Segmentation: How Is The Market Structured Across Key Categories?
The excessive daytime sleepiness market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatment; Behavioral Therapy; Continuous Positive Airway Pressure Therapy; Lifestyle Modification Programs; Combination Therapies
2) By Diagnosis Method: Polysomnography; Multiple Sleep Latency Test; Actigraphy; Clinical Evaluation; Questionnaire Based Assessments
3) By Type Of Disorder: Narcolepsy; Obstructive Sleep Apnea; Insomnia; Circadian Rhythm Disorders; Idiopathic Hypersomnia; Restless Legs Syndrome; Other Type Of Disorders
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Sleep Clinics; Ambulatory Surgical Centers; Home Care Settings
Subsegments:
1) By Pharmacological Treatment: Wake Promoting Medications; Central Nervous System Stimulant Medications; Dopamine Reuptake Inhibitor Medications; Histamine Receptor Modulating Medications
2) By Behavioral Therapy: Cognitive Behavioral Therapy For Sleep; Sleep Hygiene Education Programs; Stimulus Control Therapy; Sleep Restriction Therapy
3) By Continuous Positive Airway Pressure Therapy: Fixed Pressure Airway Therapy; Auto Adjusting Airway Therapy; Bilevel Airway Therapy; Adaptive Pressure Support Therapy
4) By Lifestyle Modification Programs: Sleep Schedule Regulation Programs; Diet And Nutrition Management Programs; Physical Activity And Exercise Programs; Stress Management And Relaxation Programs
5) By Combination Therapies: Medication And Behavioral Therapy Combinations; Airway Therapy And Lifestyle Modification Combinations; Medication And Airway Therapy Combinations; Integrated Multimodal Treatment Approaches
#Excessive Daytime Sleepiness Market Trends Influencing Long-Term Demand
Leading companies operating within the excessive daytime sleepiness market are focusing on creating innovative solutions, such as central nervous system depressants, to boost wakefulness and elevate patients’ quality of life. A central nervous system depressant is a substance that reduces nervous system activity, leading to sedation, calmness, or sleep. For instance, in September 2025, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, secured approval from the FDA for sodium oxybate oral solution, which directly treats excessive daytime sleepiness (EDS) in narcolepsy patients. This solution enhances treatment continuity by enabling virtual specialist consultations, remote prescription fulfillment, and improved patient reach in underserved regions, with the aim of expanding access, improving affordability, and aligning established pharmacotherapy with evolving digital and telehealth-driven care models for excessive daytime sleepiness.
Excessive Daytime Sleepiness Market Competitive Landscape And Leading Companies
Major companies operating in the excessive daytime sleepiness market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cleveland Clinic, EisAI Co. Ltd, Jazz Pharmaceuticals plc., Emory Healthcare Inc., Alkermes plc., Fisher & Paykel Healthcare Corporation Limited, Harmony Biosciences Holdings Inc., Medanta, Axsome Therapeutics Inc., Compumedics Limited, BIOPROJET, Apnimed Inc., Nox Health Inc., Somnogen Canada Inc., Suven Life Sciences Limited, Theranexus, XWPharma, NLS Pharmaceutics AG.
Access The Complete Excessive Daytime Sleepiness Market Report:
Excessive Daytime Sleepiness Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the excessive daytime sleepiness market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the excessive daytime sleepiness market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
